Britain’s National Health Service (NHS) has announced that it will not cover Eli Lilly’s new Alzheimer’s drug, donanemab.

A U.K. watchdog has declined to endorse Eli Lilly’s (NYSE:LLY) Alzheimer’s drug donanemab for use in the country's national health service (NHS), noting that therapy was too costly to warrant ...

Eli Lilly and Company disappointed with missed earnings, lower guidance. Click here for my review of LLY Q3 earnings and a ...

Eli Lilly (LLY) announced “positive results ... endpoint for people receiving a slightly modified titration of donanemab in adults with early symptomatic Alzheimer’s disease.

Donanemab became the second Alzheimer's drug that targets causative deposited plaque in the brain to win the coverage after ...

The stock of Eli Lilly and Company LLY has declined 10.6% in a month ... In July, Lilly won a long-awaited FDA approval for ...

Eli Lilly (LLY) announced that the Medicines and Healthcare products Regulatory Agency, or MHRA, has granted marketing authorization for donanemab, an injection for intravenous infusion every four ...

Headlines about the results of TRAILBLAZER-ALZ2 trial of Eli Lilly’s Alzheimer’s drug candidate donanemab are spreading around the world, with some going as far as to suggest this could herald ...

According to its recent 13F filing, the Duquesne Family Office headed by billionaire portfolio manager Stanley Druckenmiller ...

Trials for Eli Lilly’s Alzheimer's drug, donanemab, continue, with results expected in 2027 amid safety concerns. On Monday, Eli Lilly And Co LLY announced plans to boost its presence in the U.K ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...